Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Huanglong Granule for children with ADHD
ChiCTR2300069926Phase 4Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Xiao'er Huanglong Granules in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Beijing University of Chinese Medicine. Primary endpoint: Attention Deficit and Hyperactivity Disorder Rating Scale-IV Parent Version, Investigator Administered. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
Xiao'er Huanglong Granules
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ChiCTR2300069926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069926.